FINANCIAL SUMMARY

Immunomic Therapeutics has operated a highly capital efficient business since its inception, augmenting investor capital with revenue from licensing and collaborative deals. The company has meet major milestones, most notably completing a first-in-human Phase I study of JRC-LAMP-vax. Additional important milestones are included below.

The Company has completed a Series A preferred offering which will support further clinical development of the Company’s promising programs.

KEY MILESTONES
10/2014
ITI Files an IND for a Phase II Study for JRC2*-LAMP-Vax in Japan
09/2014
ITI is Awarded an SBIR Grant for Multi Nut Allergy Immunotherapy
07/2014
ITI Initiates a Phase IC Clinical Study
04/2014
ITI Successfully Completes Phase IB Clinical Study
07/2013
ITI completes $3M Bridge Round financing.
04/2013
ITI successfully completes Phase IA for JRC-LAMP-Vax
11/2012
“Chimeric Vaccines” patent, US Patent No. 8,318,173, issues in the US, company is provided IP protection until Apr 2022
09/2012
ITI begins Phase IA clinical study of JRC-LAMP-Vax
09/2012
ITI closes over-subscribed Series A Rights Offering round of funding at $2.9 million
09/2012
ITI receives notice of EU patent allowance for “Chimeric Vaccines” patent, a core component of LAMP-Vax IP
04/2012
ITI closes Series A round of funding for sale of $3M in common stock
04/2012
ITI receives authorization from FDA to proceed with its Phase I clinical study for Japanese red cedar immunotherapeutic vaccine.
12/2011
ITI enters into Collaborative Research and License Agreement with leading pharmaceutical company for applications in animal health, licenses several vaccines. The deal will bring several million dollars in fees and milestone payments.
03/2010
Life Sciences Greenhouse, M.A.I.N. and Trisiras Capital close on funding with immediate and future funding options of $1.75 million
03/2010
ITI selected as Frost & Sullivan Award Winner for 2010 Biotechnology Innovation of the Year Award in Vaccines
12/2009
Geron announces GRNVAC1 results from AML study meet Phase I/II endpoints. 15 of 21 patients receiving therapy continue to be in remission, some for up to 3 years
12/2006
ITI and Nature Technology agree to collaborate and cross-license vaccine technologies
10/2006
Sub-license granted to Geron Corp. for development of LAMP-telomerase cancer vaccine. ITI receives upfront fee and milestone payments as well as royalties once commercialized
09/2006
Exclusive, worldwide license to LAMP technology with Johns Hopkins University. ITI gains rights to all active LAMP-related Intellectual Property



COMPANY
TECHNOLOGY
CLINICAL
MEDIA
Immunomic Therapeutics, Inc.
Headquarters: 1214 Research Blvd, Suite 2016, Hershey, PA 17036
Phone: 717-327-1919
Lab: 15010 Broschart Rd. Ste. 250, Rockville, MD 20850
Phone: 866-515-9484

© 2007-2013 Immunomic Therapeutics, Inc.
All rights reserved
by: Design Media Land, LLC